Oncology Learning Network’s Post

Receive essential information on chronic lymphocytic leukemia (CLL) treatment in our sponsored, engaging video. Dive into the 5-year off-treatment analyses and discover the long-term effectiveness and safety of a treatment approach. https://lnkd.in/dPK39eyV

📢 View the short video below on important factors to consider when you're looking for treatment options for your patients with CLL. #LEUKEMIA #Oncology #llmcongress2024 #education #knowledge #CLL

Missed our December webcast about Chronic Lymphocytic Leukemia (CLL)? The recording is now available online, offering valuable insights into CLL. Join Dr. Versha Banerji as she explores the latest in CLL diagnosis, treatment, and future developments. 👉 Watch the recording here: https://bit.ly/48FjIIs #cll #chroniclymphocyticleukemia #bloodcancer #webcast #webinar

In this interview, Neil E. Kay, MD, offers insights into the pathobiology, treatment, and management of double refractory chronic lymphocytic leukemia (CLL). "For most patients who are double refractory, treatment with clinically approved agents [is] short-lived. So clinical trials are probably the best way to treat your double refractory CLL patient if you have one," said Dr Kay. Access the full interview here: https://lnkd.in/eB_Qqxka #JournalofClinicalPathways #JCP #Chroniclymphocyticleukemia #CLL #CLLclincialtrials

Understanding the signs and symptoms of acute lymphoblastic leukemia (ALL) in children is crucial for early detection and treatment. From anemia to swollen lymph nodes, recognizing these indicators can make a significant difference in the journey of young patients battling leukemia. #ALLSeries #LeukemiaChallenges #TreatmentStruggles #SupportNeeded

Benzene Exposure Linked to Acute Myeloid Leukemia, Aplastic Anemia, and Lymphomas https://hubs.ly/Q02xKtwQ0

“Every single patient can teach us important lessons”. This landmark paper, published in the NEJM in 2013, highlights several fundamental principles for the management of #CAR_T-cell_therapy and its life-threatening complications through the publication of the very first two cases of children with acute lymphoblastic leukemia treated with this approach. https://lnkd.in/dkM354pz

#News for #Investors and #Media: As the chronic lymphocytic leukemia (CLL) treatment landscape continues to evolve, it’s important to provide new data that can help physicians in making treatment decisions.  During #ASCO24, we will share new comparative effectiveness research underscoring the differentiated clinical profile of our BTK inhibitor in the treatment of #CLL. Learn more here: https://bit.ly/3Kf9t33

Our paper on the persistence of Chronic Lymphocytic Leukemia (CLL) stem-like populations under simultaneous in vitro treatment with curcumin, fludarabine, and ibrutinib has been accepted for publication! This finding has important implications for therapy resistance #CLL #StemCells #TherapyResistance

📢 𝐋𝐚𝐬𝐭 𝐂𝐡𝐚𝐧𝐜𝐞 𝐓𝐨 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫: 𝐁𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐑𝐞𝐥𝐚𝐭𝐢𝐨𝐧𝐬𝐡𝐢𝐩𝐬 𝐖𝐢𝐭𝐡 𝐇𝐞𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐢𝐬𝐭𝐬 𝐎𝐧𝐥𝐢𝐧𝐞 𝐂𝐨𝐮𝐫𝐬𝐞 📢 Designed specifically for patient advocates, this course offers invaluable insights and strategies for fostering productive partnerships with hematologists. Whether you're advocating for patients with Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML) or Acute Leukemia, this course will equip you with the tools you need to make a difference. ➡ REGISTER NOW: https://lnkd.in/d6YX7kSi ⏯ Hear a short overview of what this course will help you achieve: https://lnkd.in/daKkHDKA